TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Sai Life Sciences Limited
SAILIFE

Sai Life Sciences Limited Share Price

Live price, chart and which mutual funds hold this stock

TopFund Score: 74/100 · Good See breakdown ↓
…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹1,592.2

Change

-2.7 (-0.17%)

Open

₹1,590.0

Prev. Close

₹1,594.9

Day High

₹1,623.4

Day Low

₹1,581.0

Volume Analysis

Traded

265,877

Delivered

137,731

Delivery %

51.8%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (29.0%)

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (2)

  • •Strong 3-year revenue growth (21.7%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,659.14 ₹1,641.27 ₹1,616.74 ₹1,598.87 ₹1,574.34 ₹1,556.47 ₹1,531.94
Fibonacci ₹1,641.27 ₹1,625.07 ₹1,615.07 ₹1,598.87 ₹1,582.67 ₹1,572.67 ₹1,556.47
Camarilla ₹1,603.86 ₹1,599.97 ₹1,596.09 ₹1,598.87 ₹1,588.31 ₹1,584.43 ₹1,580.54

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+76.86%

1 Week

-0.98%

1 Month

+7.22%

3 Months

+29.0%

6 Months

+62.99%

1 Year

+85.48%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹208.29

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

14.23%

Net margin 16.09% × asset turnover 0.61x × equity multiplier 1.45x

Company Overview

Sector

Healthcare

Market Cap

₹33,821 Cr

P/E (TTM)

92.0

ROE

15.4%

Book Value

₹117.0

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 27 Sep 2026. Not investment advice.

TopFund Analysis

Sai Life Sciences Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 74/100. The strongest factor is Financial Strength (100/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (29.0%); promoter holding is falling. Strong 3-year revenue growth (21.7%).

TopFund Score — Fundamentals Quality

74/100 — Good

Data confidence: 77/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

100

Growth

100

Valuation

0

Cash Flow

75

Corporate Governance

34

Momentum

88

Institutional Ownership

89

Business Quality

84

Risk & Volatility

75

Liquidity

82

From Screener.in

  • +Company has delivered good profit growth of 42.2% CAGR over last 5 years
  • −Stock is trading at 13.6 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Company has a low return on equity of 12.7% over last 3 years.
  • −Working capital days have increased from 49.2 days to 69.8 days

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 18 Sep

Allotment of 24,000 Equity Shares having Face Value of Rs. 1/- as per Company''s ESOP Plan

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 17 Sep 17 Sep
Shareholder Meeting / Postal Ballot-Outcome of AGM 17 Sep 17 Sep
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 04 Sep

Sai Life Sciences to attend Jefferies 5th India Forum on 18 September 2026 in Gurgaon.

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 4 Sep 04 Sep

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 384 439 280 396 440 580 496 537 556 602 554
Expenses + 287 315 254 293 320 422 375 392 369 426 406
Operating Profit 96 125 26 102 120 158 121 146 188 177 148
OPM % 25.0% 28.0% 9.0% 26.0% 27.0% 27.0% 24.0% 27.0% 34.0% 29.0% 27.0%
Other Income + 11 3 8 10 9 10 10 15 0 16 4
Interest 23 21 21 21 23 11 12 9 10 8 8
Depreciation 31 31 31 36 34 37 38 40 44 45 46
Profit before tax 53 76 -18 55 72 119 81 112 134 139 98
Tax % 25.0% 26.0% -25.0% 25.0% 25.0% 26.0% 25.0% 25.0% 25.0% 25.0% 25.0%
Net Profit + 40 56 -14 42 54 88 60 84 100 104 73
EPS in Rs — — — — 3 4 3 4 5 5 3
Raw PDF — — — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 695 726 760 870 1,217 1,465 1,695 2,192 2,250
Expenses + 520 558 593 743 1,048 1,178 1,285 1,559 1,592
Operating Profit 176 168 167 126 169 287 410 634 658
OPM % 25.0% 23.0% 22.0% 15.0% 14.0% 20.0% 24.0% 29.0% 29.0%
Other Income + 6 18 27 28 27 29 35 40 35
Interest 24 22 33 54 81 88 78 41 35
Depreciation 44 55 80 90 99 119 139 167 175
Profit before tax 113 109 82 10 16 109 228 466 483
Tax % 35.0% 30.0% 25.0% 36.0% 39.0% 24.0% 25.0% 25.0% —
Net Profit + 73 76 61 6 10 83 170 349 362
EPS in Rs — — — — — — 8 16 17
Dividend Payout % 0.0% 0.0% 0.0% 1,117.0% 676.0% 0.0% 0.0% 0.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Reserves 703 778 845 861 870 957 2,108 2,463
Borrowings + 249 304 637 752 933 928 352 288
Other Liabilities + 247 312 318 527 358 359 665 841
Total Liabilities 1,215 1,410 1,817 2,157 2,179 2,262 3,146 3,613
Fixed Assets + 373 641 701 751 1,037 1,180 1,488 1,815
CWIP 116 91 246 410 151 107 124 270
Investments 0 0 0 0 2 2 2 50
Other Assets + 726 679 870 997 989 973 1,531 1,477
Total Assets 1,215 1,410 1,817 2,157 2,179 2,262 3,146 3,613
Equity Capital 16 16 17 18 18 18 21 21

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 129 116 -36 105 219 263 314 509
Cash from Investing Activity + -158 -262 -260 -102 -99 -191 -536 -395
Cash from Financing Activity + 268 -4 296 72 -201 -95 301 -124
Net Cash Flow 239 -150 -1 75 -80 -24 79 -9
CFO/OP 90 81 -13 90 132 96 82 86
Free Cash Flow -28 -157 -298 -102 148 82 -55 -83

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 35.23% → 34.53%
  Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Public 41.08% 39.21% 28.64% 12.65% 12.49% 12.69% 13.11%
Promoters 35.23% 35.16% 35.15% 34.95% 34.7% 34.61% 34.53%
FII 11.72% 12.36% 14.57% 22.5% 21.41% 21.17% 19.65%
DII 11.95% 13.26% 21.64% 29.92% 31.41% 31.54% 32.71%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Sai Life Sciences Limited (this stock) 33,821 92.0 13.61 15.4%
Krishna Inst Of Med Sci L 32,765 157.0 13.88 11.3%
Dr. Lal Path Labs Ltd. 32,299 57.4 12.83 22.3%
Wockhardt Limited 36,814 92.3 7.45 6.11%
Emcure Pharmaceuticals L 37,595 36.5 7.59 20.1%
Narayana Hrudayalaya Ltd. 38,040 44.1 8.38 20.5%
Neuland Lab Ltd. 28,085 56.4 14.98 21.2%

Which Mutual Funds Hold Sai Life Sciences Limited?

Frequently Asked Questions about Sai Life Sciences Limited

Community Sentiment

What are other investors saying about Sai Life Sciences Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.